Blood naltrexone and 6-β-naltrexol levels following naltrexone implant: Comparing two naltrexone implants

Addiction Biology

Volumn 9, Issue 1, 2004, Pages 59-65

  Hulse, G K ^a   Arnold Reed, D E ^a   O'Neil, G ^a,b   Chan, C T ^b   Hansson, R ^c   O'Neil, P ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Australian Med Procedures Res F   (Australia)

^c Chemistry Centre Western Australia   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NALTREXOL; NALTREXONE; OPIATE ANTAGONIST;

ADULT; ARTICLE; AUSTRALIA; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG IMPLANTATION; DRUG RELEASE; DRUG SYNTHESIS; FEMALE; HEROIN DEPENDENCE; HUMAN; MALE; PRIORITY JOURNAL;

ADULT; BODY MASS INDEX; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG IMPLANTS; FEMALE; FOLLOW-UP STUDIES; HEROIN DEPENDENCE; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; RETROSPECTIVE STUDIES;

EID: 2342527785     PISSN: 13556215     EISSN: None     Source Type: Journal    
DOI: 10.1080/13556210410001674103     Document Type: Article

References (16)

1. Julius D. NIDA's naltrexone research program. In: Julius D, Renault P, editors. Narcotic antagonists: naltrexone. NIDA Research Monograph no. 9. Rockville, MD: National Institute of Drug Abuse, 1976:5-11.
2. Tennant PS, Rawson RA, Cohen AJ, Mann A. Clinical experience with naltrexone in suburban opioid addicts. J Clin Psychiatry 1984;45:42-5.
3. San L, Pomarol G, Peri JM, et al. Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. Br J Addict 1991;86:983-90.
4. Hulse GK, Basso MR The association between naltrexone compliance and daily supervision. Drug Alcohol Rev 2000;19:41-8.
5. Willette RE. Narcotic antagonists. An alternative for treating opioid dependence. Am Pharm 1982;NS22:44-6.
6. Brewer C. Naltrexone implants for opiate addiction: new life for a middle aged drug. Pharm J 2001;267:260.
7. Brewer C. Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases. Addict Biol 2002;7:321-3.
8. Comer SD, Collins ED, Kleber HD, et al. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl), 2002;159:351-60.
9. Bugge CJL, Grun I, Stanfor K, Tan MS, Garcia DB. Determination of naltrexone and 6-β-naltrexol in human plasma by LC-MS-MS. Austin, Texas: CEDRA Corporation, 1996.
10. Olmedo RE, Hoffman RS, Rowland MA, Nelson LS. Death as a complication of ultrarapid opioid detoxification (UROD). J Toxicol Clin Toxicol 2000;38:536-7.
11. Vereby K, Volavka J, Mule SJ, Resnik RB. Naltrexone: disposition, metabolism and effects after acute and chronic dosing. Clin Pharmacol Ther 1976;20:315-28.
12. Navaratnam V, Jamaludin A, Raman N, Mohamed M, Mansor SM. Determination of naltrexone dosage for narcotic agonist blockade in detoxified asian addicts. Drug Alcohol Depend 1994;34:231-6.
13. Chiang CN, Hollister LE, Gillespie HK, Foltz RL. Clinical evaluation of a naltrexone sustained-release preparation. Drug Alcohol Depend 1985;16:1-8.
14. Ferrari A, Bertolotti M, Dell'Utri A, Avico U, Sternieri E. Serum time course of naltrexone and 6beta-naltrexol levels during long term treatment in drug addicts. Drug Alcohol Depend 1998;52:211-20.
15. Gonzalez J, Brogden R. Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opiate dependence. Drugs 1988;35:192-213.
16. O'Neil G, Hulse G, Armstrong J, Little M, Murray L. Letter to the editor. Acad Emerg Med 2002;9:960.